A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-Thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion.

Trial Profile

A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-Thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Fibrinolysin human (Primary)
  • Indications Embolism and thrombosis; Peripheral arterial occlusive disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRIORITY
  • Most Recent Events

    • 11 Jun 2012 Results were reported in a Grifols media release, and will be published in the June issue of the Journal of Thrombosis and Haemostasis.
    • 08 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 08 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top